A Clinical Study to Evaluate if Benzalkonium Chloride (BAK) in a Quinolone Eyedrop Reduces the Likelihood of Developing Resistant Organisms

Anti-biotic Resistance Clinical Trial

Status Completed

Clinical Trial Summary

The purpose of this study is to assess if the presence of BAK in a fluoroquinolone in the study eye affects the development of resistant bacteria on the conjunctiva based upon changes in the surface flora over the course of 2 weeks of topical treatment in healthy adult subjects.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science

Related Conditions & MeSH terms

Anti-biotic Resistance

Clinical Trial Details

NCT number	NCT00874887
Study type	Interventional
Source	Allergan
Contact
Status	Completed
Phase	Phase 4
Start date	March 2009
Completion date	October 2009

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT00722410` - Probiotics for Eradication of Carbapenem Resistant Klebsiella Pneumonia	Phase 1/Phase 2
Completed	`NCT01321606` - Impact of Probiotics for Reducing Infections in Veterans: The IMPROVE Study	Phase 2
Completed	`NCT00933556` - A Pilot Trial to Determine the Efficacy of VSL#3 for Reducing Colonization by VRE	Phase 2